Company Overview and News

 
UOB named Best Regional Bank of the Year for Belt and Road Initiative in Southeast Asia

2018-09-19 theedgemarkets
SINGAPORE (Sept 19): United Overseas Bank (UOB) has been named Best Regional Bank of the Year for the Belt and Road Initiative (BRI) in Southeast Asia at the 2018 Asiamoney New Silk Road Finance Awards.
UOVEF UOVEY U11

 
The State of the Nation: Slower export growth ahead on external uncertainties

2018-09-17 theedgemarkets
EXPORT growth in July came as a surprise to everyone, beating consensus estimate of 4.7% to register 9.4% year on year. This came on the back of higher electrical and electronic (E&E) exports and a slower drop in commodity exports.
UOVEF UOVEY U11

5
Public Bank among the most expensive in the region

2018-09-14 thestar.com.my
High returns: Public Bank, which is 22.8-owned by Teh, is trading at 2.45 times its book value.
HLFBF STAN PBLOF MLYNF 1295 CBQS 1023 STAB STAC SCBFF STAN UOVEF MLYBY C 55BC 1082 U11 CIMDF 1155 CGBBW 580001 UOVEY 2888 5819

 
Fresh push for banking M&As

2018-09-14 thestar.com.my
TWO decades since the 1997/98 Asian Financial Crisis (AFC), the regional banking landscape has changed much, especially in the last few years with the emergence of online and mobile banks, as well as peer-to-peer lending and payment practices.
1155 UOVEF MLYBY MLYNF UOVEY U11

 
Most rise as trade war fears ease; Thailand sees best week in 6 months

2018-09-14 theedgemarkets
(Sept 14): Most Southeast Asian stock markets rose on Friday, with Thai shares posting their best weekly gain since mid-March, as trade worries eased after China welcomed an invitation from the United States for a new round of talks.
UOVEF DBSDY D05 JBFCF DBSDF JFC UOVEY JBFCY U11

 
Ringgit poised to halt 12-week run of losses

2018-09-14 theedgemarkets
KUALA LUMPUR (Sept 14): Ringgit heads for its first weekly gain in three months as crude prices rally and the dollar surrenders recent gains.
UOVEF UOVEY U11

 
Indonesia, Philippines jump on U.S.-China trade talks optimism

2018-09-13 theedgemarkets
(Sept 13): Indonesian shares jumped on Thursday and Philippine stocks saw respite after six days of declines, on hopes that China and the United States could strike a deal in their bitter tariff dispute during a new round of trade talks.
UOVEF URC UOVEY UVRBY PETFF U11 UVRBF

 
SGX sees share buyback boom: Why and what does it mean for investors?

2018-09-12 channelnewsasia
SINGAPORE: Singapore-listed companies have been repurchasing more of their own shares this year, with stock buybacks hitting a near three-year high last month, and analysts think this trend could continue for the rest of 2018 amid a volatile market.
SPXCY UOVEF SPXCF C09 UOVEY CDEVF CDEVY U11 O39 S68

 
Yes Bank raises $400 million through syndicated loan facility

2018-09-11 moneycontrol
Private sector lender Yes Bank Tuesday said it has raised $400 million (approx Rs 2,894 crore) through syndicated loan facility, borrowed out of its IFSC Banking Unit (IBU) in Gujarat International Finance Tec City (GIFT). The bank said this amount will be utilised to support the IBU's growing business.
YESBANK UOVEF WBC WBC UOVEY WEBNF 532648 YYBKY WBK U11 SBAZ

 
UOB reaffirms joint commitment with BKPM to promote foreign direct investments into Indonesia

2018-09-07 theedgemarkets
SINGAPORE (Sept 7): United Overseas Bank and Indonesia’s Investment Coordinating Board (Badan Koordinasi Penanaman Modal, or BKPM) have reaffirmed their joint commitment to promote foreign direct investments (FDI) into Indonesia.
UOVEF UOVEY U11

1
‘OPR to stay unchanged for rest of 2018 amid slower growth’

2018-09-06 theedgemarkets
KUALA LUMPUR: Economists expect Bank Negara Malaysia (BNM) to maintain the overnight policy rate (OPR) at 3.25% for the rest of this year amid the slower economic growth.
NMR UOVEF 8604 N33 UOVEY NRSCF U11

 
U Mobile gets RM1b loan to expand ops

2018-09-05 thestar.com.my
Deal sealed: (from left) Berjaya Infrastructure Sdn Bhd director Loh Paik Yoong, UOB Malaysia deputy chief executive officer Hendra Gunawan, Wong, U Mobile chairman Tan Sri Vincent Tan, U Telemedia Sdn Bhd director Kenneth Chang and Berjaya Retail Bhd director Chow Lean Keat at the signing ceremony.
UOVEF UOVEY U11

5
Hedge Funds Face a New Threat From Richest Families in Asia

2018-09-05 theedgemarkets
(Sept 5): They’ve already come for the talent, poaching traders from the likes of Millennium Management LLC. Now Asia’s family offices are going after the hedge fund industry’s clients, too.
JBK UOVEF DB GSC TFG U11 GSJ GS GLSSP UOVEY GJS

 
World's top activist fund sets eyes on one of Singapore's banks

2018-08-28 malaymail
SINGAPORE, Aug 28 — The world’s best-performing activist fund returned 103 per cent in seven months by targeting mainly smaller Asian companies in industries from commodities to engineering and food.
UOVEF DBSDY D05 DBSDF UOVEY U11 O39

 
UOB and StarHub ink MoU to help SMEs accelerate their digitisation efforts

2018-08-27 theedgemarkets
SINGAPORE (Aug 27): StarHub and United Overseas Bank (UOB) have signed a memorandum of understanding (MoU) to help accelerate the digitsation efforts of small- and medium-sized enterprises (SMEs) through the joint exploration, development and provision of digital solutions.
UOVEF UOVEY U11

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 911271302